(Q35652340)

9 August 2017

title

Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden (English)

1 reference

9 August 2017

Herbert Y Meltzer

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

20 February 2007

1 reference

Proceedings of the National Academy of Sciences of the United States of America

9 August 2017

number of pages

2

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

9 August 2017

volume

104

1 reference

9 August 2017

issue

9

1 reference

9 August 2017

page(s)

3019-3020

1 reference

The metabolic syndrome: concepts and controversy

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

AMP-activated protein kinase as a drug target.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

The metabolic syndrome and schizophrenia: a review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

The new and evolving pharmacotherapy of schizophrenia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Antipsychotic-induced weight gain: a comprehensive research synthesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

27 July 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Treatment of psychosis in Parkinson's disease: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Role of AMP-activated protein kinase in mechanism of metformin action

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

Clozapine-induced weight gain: prevalence and clinical relevance

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1805573

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

25 September 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.0700090104

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17360600

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1073/PNAS.0700090104

1 reference

9 August 2017

0 references

1 reference

9 August 2017

1 reference